期刊
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
卷 6, 期 8, 页码 1519-1532出版社
WILEY
DOI: 10.1002/acn3.50855
关键词
-
资金
- Cure SMA/Families of SMA Canada [KOT-1819]
- Muscular Dystrophy Association (USA) [575466]
- Canadian Institutes of Health Research (CIHR) [PJT-156379]
- E-Rare-2 program from the CIHR [ERL-138414]
- Italian Association of SMA Families (Famiglie SMA)
- Fondazione Telethon (Italy) [GUP15014]
- Cure SMA [MU1415]
- Fight SMA
- Muscular Dystrophy Association [417757]
- Tenovus Scotland [E15/4]
- Newlife foundation for disabled children [SG/14-15/08]
- UK SMA Research Consortium
- SMA Europe
- Tenovus (Scotland)
- Euan Macdonald Centre for Research into Motor Neurone Diseases
- SMA Angels Charity
- National Institutes of Health (NIH) [DK59637]
- NIH [2U2C-DK093000]
- Frederick Banting and Charles Best CIHR Doctoral Research Award
Objective Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder leading to paralysis and subsequent death in young children. Initially considered a motor neuron disease, extra-neuronal involvement is increasingly recognized. The primary goal of this study was to investigate alterations in lipid metabolism in SMA patients and mouse models of the disease. Methods We analyzed clinical data collected from a large cohort of pediatric SMA type I-III patients as well as SMA type I liver necropsy data. In parallel, we performed histology, lipid analysis, and transcript profiling in mouse models of SMA. Results We identify an increased susceptibility to developing dyslipidemia in a cohort of 72 SMA patients and liver steatosis in pathological samples. Similarly, fatty acid metabolic abnormalities were present in all SMA mouse models studied. Specifically, Smn(2B/-) mice displayed elevated hepatic triglycerides and dyslipidemia, resembling non-alcoholic fatty liver disease (NAFLD). Interestingly, this phenotype appeared prior to denervation. Interpretation This work highlights metabolic abnormalities as an important feature of SMA, suggesting implementation of nutritional and screening guidelines in patients, as such defects are likely to increase metabolic distress and cardiovascular risk. This study emphasizes the need for a systemic therapeutic approach to ensure maximal benefits for all SMA patients throughout their life.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据